Critiquing the Skeptics re “Funny how you never see Orac and this person in the same place at the same time”

“Funny how you never see Orac and this person in the same place at the same time”

#1 – Marc Stephens Is Insane – 3/30/2013

“Eric Merola and DJT have already resorted to making fun of Orac’s “friend’s” presentation on the #burzynski thread

“They are now disputing the “sugar does not feed cancer” claim that is raised in the video”

“NOW DISPUTING” ?

I do NOT need to waste my time “DISPUTING” the

“sugar does not feed cancer”

claim

That has already been done by organizations in the USA, as I noted here; the bottom 1/4th:
https://stanislawrajmundburzynski.wordpress.com/2013/04/02/critiquing-david-h-gorski-quackademic-medicine

#2 – Marc Stephens Is Insane – 3/30

“To wit, the twit:”
http://twitpic.com/cffrfv

Does this mean that some poor sod has to suffer through an Orac’s “friend’s”

“Alternative sleep therapy”

video in order to determine where THIS reference came from?

It’s NOT like ORAC’s “friend” did NOT already do a fabulous job at estranging the whole “Faith-Based” segment of society

Gorski, care to repeat your little insignificant presentation at the Southern Baptists’ Convention, for example?

#8 – Neil B. Feldman – Rockville, MD – 3/30

“Orac, I am the fellow in the audience (with stage IV RCC on Sutent) who asked about nutrition and the fact that marginalizing this vital subject just pushes it further into the arms of sCAMers”

The man I mentioned at “20.” of my “Critiquing David H. Gorski – Quackademic Medicine” blog post

#9 – David James – 3/30
http://www.skeptical.gb.net
“MSII – I think you’ll find Orac’s friend has posted this as a direct conciquence of Eric and DJT linking to it”

“Conspiracy Theorist” David James; as can be expected from a fair number of “Skeptics,” as a “conciquence” of being a “Skeptic,” gets it WRONG

I did NOT link to it on Twitter

THAT, was Eric

“Personally, I think it’s odd that you only ever see them in the same place at the same time… I mean seriously guys, get a room!!”

I suggest a “Time-Out” for you in your own “get a” personalized rubber room

#10 – JayBee – Everywhere Else –
3/30

“MSII #5:
Jake’s appearance was neat and clean enough

I was more entertained by his attempts to engage Dr. Gorski after the meeting by loudly and repeatedly asking”

“Since when is everywhere else a geographical location?”

There were much better subjects that could have been “broached” with Orac’s “friend”

Like:

“Would you like some sugar with your Black Crowes?

#11 – Melissa G – 3/30

“Orac, your “friend’s” HEAVY SIGHS at the Quackademic medicine during the presentation were the most awesome part!”

Ohhh, trust me

THAT was NOWHERE near close to being:

“the most awesome part!”

“Poor Jake

He just absolutely does not understand the meaning of cherry-picking”

Do NOT worry

Do NOT be afraid

Orac’s “friend” provided him with a plethora of examples of:

“cherry-picking”

“You TOTALLY pwned him … “

“Someone” got “pwned,” his name begins with the Big “O,” and he resides behind a CAM (Clear And Magic) curtain, in the “Land of Oz,” similar to the Emperor who has no clothes

” … he pulled out of his arse”

EXACTLY!!!

#13 – S – 3/30

“Jake’s appearance was neat and clean enough

I was more entertained by his attempts to engage Dr. Gorski after the meeting by loudly and repeatedly asking”

“Since when is everywhere else a geographical location?”

Is there an ECHO ECHo ECho Echo echo in here from #10?

#22 – Alain – 3/30

” … for some peoples, it’s all about me, myself and I”

Or in Orac’s and his “friend’s” case:

it’s all about @OracKnows, @gorskon and @ScienceBasedMed

#39 – Quokka – Pretoria South Africa – just for a change – 4/1

“Posting here will make a difference to others who are beginning to question”

Maybe as long as you do NOT begin to

“question”

Orac and his “Oracolytes”
http://scienceblogs.com/insolence/2013/03/30/funny-how-you-never-see-orac-and-this-person-in-the-same-place-at-the-same-time

Advertisements

Critiquing the Critics at Sciencebasedmedicine (Burzynski: Cancer Is A Serious Business, Part 2:)

Like the first Burzynski movie, only more so?
http://www.sciencebasedmedicine.org/index.php/burzynski-cancer-is-a-serious-business-part-2-like-the-first-burzynski-movie-only-more-so

“Elburto

Merola is subhuman filth

We’re accused of bullying cancer patients online for daring to say

“there’s no evidence”,

yet he can effectively say

“Those parents killed their children

They weren’t Burzynskiite Twoo Believers, and look at the result” on film, without feeling remotely troubled about it

and how it was abused by Stan the Conman*

For Merola to stoop so low as to place the death of these tiny children on the heads of their parents, is something I cannot understand

It makes me with I believed in god and hell

It’s just unfathomable that someone could be so base and callous about dead children

But no, we’re the evil ones

*Almost as bad as this is Stan’s new spin doctor’s claim that the fundraising families have lied about the costs of “treatment” in order to fleece the public”

After reading the above comments that were Eblurto’d out:

“It makes me with”

I had NOT read it

Maybe ElBlurto should have read THIS:

“Vasha

A lot of the Burzynski publicists’ favorite cases seem to have been cancers where the chances weren’t good right from the beginning — diffuse pontine glioma, glioblastoma multiforme, etc

This allows them to paint doctors as cold for not promising much hope

It’s the old

“Doctors sent me home to die!” meme

Patients who want to be given hope, above all hope, sometimes interpret bad news as deliberate cruelty”

You mean all of Burzynski’s success were because of Doctors misdiagnoses; since they should have told the patient to go home and “Heal Thyself” through “Spontaneous Regression” ?

Immunity over inability:

The spontaneous regression of cancer
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3312698
J Nat Sci Biol Med. 2011 Jan-Jun; 2(1): 43–49.
doi: 10.4103/0976-9668.82318
PMCID: PMC3312698

“Guy Chapman

How could you be so heartless, Dr Gorski?

Eric Merola almost bankrupted himself to bring us this compelling tale of the brave maverick doctor whose success in promoting a non-toxic cure for cancer has been ruined by evil skeptics in the pay of Big Pharma!

Surely that outweighs all the suffering and crippling financial burden imposed on patients?

Surely we must give Burzynski a free pass form all criticism of his unethical and frankly incompetently conducted trials, in recognition of the selfless sacrifice of a man who might not make any money out of his latest long-form advertisement?”

You mean the man a “Skeptic Mule” questioned about funding because he used a tactic familiar to a lot of critics, the “I can’t be bothered to research” tactic:
http://scienceblogs.com/insolence/2013/03/14/five-things-i-learned-second-hand-from-the-recent-screening-of-burzynski-cancer-is-serious-business-part-2

“I can take satisfaction that when Brian got up to ask a question, identified himself as a Skeptic

(a “skeptic mule,” to be precise),

and, prefacing his question with the observation that Merola accused all of us of being funded by pharma,

asked him about how he has funded his movies,

Merola reportedly looked none too pleased. It was at this point that I think we get a full lesson in where Merola’s at”
http://www.randi.org/site/index.php/swift-blog/2050-qburzynski-iiq-is-more-of-the-same.html

“Xplodyncow

Ah, I get it now

The Skeptics™ are the cranky old person at the end of the street, the one who screams,

“Get off my lawn, damn kids!” at passersby, launching into meandering screeds when provoked

“In my day, we didn’t have any of this ‘antineoplaston’ tomfoolery

No, when you got cancer, you suffered until you died!

It was character building.””

Or THIS:
https://stanislawrajmundburzynski.wordpress.com/2013/03/24/the-skeptics

“The Skeptics” (Burzynski: Cancer is Serious Business, Part II)

The “group” “The Sketics” claims is NOT a “group” and which allegedly does NOT spread “misinformation”

Why do some Burzynski critics claim they are NOT a “group” when they use the same blog Title ?

2/12/2013 – Josephine Jones @_JosephineJones
Burzynski: in dire need of credibility
http://josephinejones.wordpress.com
2/13/2013 – 21stFloor @The21stFloor – Keir Liddle @endless_psych (Riddle Like)
Burzynski: In dire need of credibility

http://www.thetwentyfirstfloor.com
2/7/2013 – Josephine Jones @_JosephineJones
Burzynski: harming without care?
http://josephinejones.wordpress.com
2/13/2013 – 21stFloor @The21stFloor – Keir Liddle @endless_psych (Riddle Like)
Burzynski: Harming without care?

http://www.thetwentyfirstfloor.coem
Why do some Burzynski critics claim they are NOT a “group” when they refer to each other’s blog ?

1/6/2013 – PZ Myers
Let’s make Houston cancer quack Burzynski pay!
http://scienceblogs.com/pharyngula/2013/01/06/lets-make-houston-cancer-quack-burzynski-pay

“We’re coming up on Burzynski’s 70th birthday”

Citing and linking to 1/4/2013 blog

1/7/2013 – Orac @oracknows David Gorski @gorskon (David H. Gorski) #sciencebasedmedicine
Let’s make Dr. Stanislaw Burzynski do something good for cancer patients for a change
http://scienceblogs.com/insolence/2013/01/07/lets-make-dr-stanislaw-burzynski-do-something-good-for-cancer-patients-for-a-change

“That’s why I like the idea of the campaign that Bob Baskiewicz has come up with to wish Dr. Burzynski a happy birthday this year, skeptic style:”

Citing and linking to 1/4/2013 blog:

1/4/2013 – Bob Blaskiewicz @rjblaskiewicz
Happy Birthday, Dr. Burzynski!
http://thehoustoncancerquack.com/2013/01/04/happy-birthday-dr-burzynski

Why do some Burzynski critics claim they are NOT a “group” when they twit on twitter they congratulate each other re blogs and such ?

1/28/2013 – David Gorski @gorskon Orac @oracknows (David H. Gorski) #sciencebasedmedicine

Re C0nc0rdance
https://stanislawrajmundburzynski.wordpress.com/2013/03/23/my-review-of-c0nc0rdance

3/4/2013 – 21stFloor @The21stFloorr – Keir Liddle @endless_psych (Riddle Like)
http://tmblr.co/ZXehnvfULh9y
Re David Gorski @gorskon Orac @oracknows (David H. Gorski) #sciencebasedmedicine

3/5/2013 – 21stFloor @The21stFloor – Keir Liddle @endless_psych (Riddle Like)
http://tmblr.co/ZXehnvfcJhax
Re Josephine Jones @_JosephineJones

3/15/2013 – Bob Blaskiewicz @rjblaskiewicz

retweeted David Gorski @gorskon Orac @oracknows (David H. Gorski) #sciencebasedmedicine

3/22/2013 – Josephine Jones @_JosephineJones retweeted:
http://p.ost.im/p/dxSYBC
Guy Chapman @SceptiGuy

3/22/2013 – Josephine Jones @_JosephineJones retweeted:
http://www.pbs.org/ombudsman/index.html
Bob Blaskiewicz @rjblaskiewicz

Why do some Burzynski critics claim they are NOT a “group” when they comment on each others blogs ?

Post #2 – rjblaskiewicz @rjblaskiewicz (Bob Blaskiewicz) – Wisconsin – 1/7/2013
Thanks, PZ

Post#8 – Orac @oracknows David Gorski @gorskon (David H. Gorski) #sciencebasedmedicine – 1/8/2013
http://scienceblogs.com/pharyngula/2013/01/06/lets-make-houston-cancer-quack-burzynski-pay
Let’s make Houston cancer quack Burzynski pay!
Posted by
PZ Myers 1/6/2013

“Read the latest on Burzynski from
Science-Based Medicine” (David Gorski @gorskon Orac @oracknows David H. Gorski) #sciencebasedmedicine

Now that Burzynski has gotten off in 2012, Burzynski The Movie will spawn a sequel in 2013
http://www.sciencebasedmedicine.org/index.php/burzynski-movie-spawns-a-sequel
David Gorski @gorskon Orac @oracknows (David H. Gorski) #sciencebasedmedicine – 12/3/2012

Post #2 – Robert Blaskiewicz @rjblaskiewicz (Bob Blaskiewicz) – 1/7/2013

“The Skeptics” non- group activity on Forbes:

Forbes Learns a Lesson, but Not the Right One: Censorship and Bias re: A Film Producer, A Cancer Doctor, And Their Critics
https://stanislawrajmundburzynski.wordpress.com/2013/05/05/forbes-learns-a-lesson-but-not-the-right-one-censorship-and-bias-re-a-film-producer-a-cancer-doctor-and-their-critics/

My review of C0nc0rdance

Orac (David H. Gorski) blogged:

(although we do have C0nc0rdance)
http://www.sciencebasedmedicine.org/index.php/three-myths-about-stanislaw-burzynski-and-the-skeptics

as if C0nc0rdance is a reliable source

1/24/2013 – C0nc0rdance posted a video on YouTube

The Burzynski Clinic

“Feel free to pass this on to anyone considering their options in alternative cancer treatments at the Burzynski Clinic

It’s also CCMA, so feel free to mirror or repost

AUTHOR’S NOTE:

I caught an error in post-production:

The Burzynski Clinic has only started 61 clinical trials, not 62

The last came up in my query because one of the authors has the same name

Otherwise the figures are correct”

“Fact 1:

The Burzynski Clinic has attempted 61 clinical trials, but only completed 1

Check it out here:”
http://www.clinicaltrials.gov/ct2/results?term=Burzynski&Search=Search

“Fact 2:

The Burzynski Clinic charges
its patients to participate in a study of their patented medication that exposes them to risk”

http://scienceblogs.com/insolence/2010/05/05/harnessing-peoples-good-to-pay-for-woo

“Fact 3:

The Burzynski Clinic makes heavy use of marketing techniques not normally associated with clinical practices and not in the best spirit of research medicine

For example, you can see here that they are abusing libel laws to silence critics”
http://www.guardian.co.uk/commentisfree/cifamerica/2011/nov/30/burzynski-clinic-cancer-libel-laws

And threatening and bullying of a 17 year old blogger by a media consultant:”
http://rhysmorgan.co/burzynski-morally-reprehensible

1:10-I want to present the case of Dr. Stanislaw Burzynski in my home state of Texas

1:30-cancer researcher

Maybe you should consider sticking to cancer research

1:32_3 red flags

Hearing this raised a “red flag” that your claims might be suspect

1:57_3 undisputed facts

And this proved it

2:00-Fact 1 clinical trials

The “FACT” one should know is that clinicaltrials . gov does NOT contain the same data as the National Cancer Institute (NCI) at the National Institutes of Health (NIH) cancer . gov web-site:

61 TOTAL
1 – Not Yet Recruiting (Open)(Phase 3)
1 – Closed
2 – Terminated (Withdrawn due to slow enrollment)
7 – Withdrawn (This study has been withdrawn prior to enrollment)
10 – Recruiting (Open)
11 – Open (1 Not Yet Recruiting / 10 Recruiting)
40 – Active, not recruiting (Closed)
http://cancer.gov/clinicaltrials/search/results?protocolsearchid=11475951

http://cancer.gov/clinicaltrials/search/results?protocolsearchid=11476036

On clinicaltrials . gov, if you select one of the “Unknowns,” it displays:

“Verified ____, ____ by National Cancer Institute (NCI)”

“Information provided by:
National Cancer Institute (NCI)”

“Further study details as provided by National Cancer Institute (NCI):”

Contact: Stanislaw R. Burzynski, MD, PhD

Investigators
Study Chair: Stanislaw R. Burzynski, MD, PhD

2:33-Every clinical trial has to register before starting

FALSE: I contacted the National Cancer Institute (NCI) at the National Institutes of Health (NIH) and was advised:

Not every cancer clinical trial taking place in the United States is listed on our NCI clinical trials database

The investigators must apply and follow guidelines to be included

4:08-Fact 2 – The Burzynski Clinic charges patients to receive clinical trial medications

FALSE: Burzynski does NOT charge for antineoplastons

By comparison:

St. Jude:
http://www.stjude.org/stjude/v/index.jsp?vgnextoid=403c6f9523e70110VgnVCM1000001e0215acRCRD

2/15/2012 – the U.S. Department of Health and Human Services has awarded St. Jude Children’s Research Hospital $4,314,800 for a childhood cancer survivor study

The new federal funds will be distributed by the National Cancer Institute (NCI)
http://cohen.house.gov/press-release/cohen-st-jude-receive-43-million-childhood-cancer-survivor-study

Tax-Exempt
Receives Federal Grants / Funds
http://www.stjude.org/stjude/v/index.jsp?vgnextoid=b7e79bb8a0cf5110VgnVCM1000001e0215acRCRD&cpsextcurrchannel=1

Donations to St. Jude are tax deductible as allowed by law
http://www.stjude.org/stjude/v/index.jsp?vgnextoid=6f8afa3186e70110VgnVCM1000001e0215acRCRD&vgnextchannel=2f62940504f9a210VgnVCM1000001e0215acRCRD

FORBES: CEO – $742,718
http://www.forbes.com/fdc/welcome_mjx.shtml

Burzynski does NOT receive Federal Grants / Funds, is NOT Tax-Exempt, and you can NOT write off a contribution as a tax deduction on your Tax Return

6:32-Burzynski movie
doesn’t examine the issue from both sides

FACT: None of the oncologists who originally diagnosed each patient presented in this film would agree to go on-camera, or submit a written statement
1:44:44 – 1:44:52
(http://www.burzynskimovie.com)

6:41-Conspiracy

FACT: See these 2 links:
http://burzynskimovie.com/images/stories/transcript/Documents/BurzynskiTriesToExposeNCI.pdf

http://stanislawrajmundburzynski.wiki-site.com/index.php/Main_Page

Fact 3: it is referred to as “Beating a Dead Horse” when a point that is moot, is be labored by critics

Stanislaw Rajmund Burzynski Publications

PUBLICATIONS BY STANISLAW RAJMUND BURZYNSKI AND ASSOCIATES
http://www.cancermed.com
2010
http://neuro-oncology.oxfordjournals.org/content/12/suppl_4/iv78.full.pdf

http://neuro-oncology.oxfordjournals.org/content/12/suppl_4/iv69.full.pdf?sid=252d3806-c450-4df0-8cf8-8ddf54d68db4
Burzynski, S.R, Weaver, R.A., Janicki, T.J., Burzynski, G.S., Szymkowski, B., Acelar, S.S.
OT-15
Preliminary results of a phase II study of antineoplastons A 10 and AS2-1 (ANP) in adult patients with recurrent mixed gliomas
Neuro-Oncology 2010;12(Suppl. 4):iv72
http://m.neuro-oncology.oxfordjournals.org/content/12/suppl_4/iv69.abstract

http://neuro-oncology.oxfordjournals.org/content/12/suppl_4/iv69.abstract

http://neuro-oncology.oxfordjournals.org/content/12/suppl_4/iv69.abstract?sid=252d3806-c450-4df0-8cf8-8ddf54d68db4

2010
http://neuro-oncology.oxfordjournals.org/content/12/suppl_4/iv7.full.pdf
Patil, S., Burzynski, S.R, Mrowczynski, E., Grela, K.
CB-15
Targeting microRNAs in glioma cells with antineoplastons
Neuro-Oncology 2010;12(Suppl. 4):iv10
http://neuro-oncology.oxfordjournals.org/content/12/suppl_4/iv7.abstract

https://docs.google.com/viewer?a=v&q=cache:IBvnFSDxjOwJ:antineoplaston.us/yahoo_site_admin/assets/docs/Targeting_Micrornas_in_Glioma_Cells_with_ANPs.283112914.pdf+&hl=en&gl=us&pid=bl&srcid=ADGEEShl7XBRL_UID1XOC98nhQmB0nToXiJlf6Hg-0MVRvi_dlXz4Ve0m9bRBbopo4WpuQt5jnXx6vOiz7lDUgSgIwDXcPJzgbatKEpiZFto3I-xkUXRaZunccxR4Y7IVbGY6WxXMj0s&sig=AHIEtbTlGZPqH8vHhO9cQLP-hjrZi2lQgw&overridemobile=true&chrome=true#

2010

Burzynski, S.R, Weaver, R.A., Janicki, T., E. Szymkowski, B., Acelar, S.S., Burzynski, G.S.
A phase II study of antineoplaston A10 and AS2-1 injections in children with low i J r a d e astrocy1omas
Neuro-Oncology 2010 ; 12 (6):ii95

2010

Patil, S., Burzynski, S.R, Mrowczynski, E., Grela, K.
Antineoplastons initiate caspase induced apoptosis by suppressing survivin expression in U87 glioblastoma cells
Neuro-Oncology 2010;12(6):ii87

2009

Weaver, RA, Szymkowski, B., Burzynski, S.R
Over a 10-year survival and complete response ofa patient with diffuse intrinsic brainstem glioma (DBSG) treated with antineoplastons (ANP)
Neuro-Oncology 2009;11:923

2009

Burzynski, S.R., Janicki, T.J., Weaver, RA , Szymkowski, B., Burzynski, G.S.
Phase II study of antineoplastons A 10 and AS2-1 in patients with brainstem glioma:
Protocol BC-BT-11
Neuro-Oncology 2009;11:951

2009

Burzynski, S.R.
The coming pandemic of liver cancer:
In search of genomic solutions
In: American Academy of Anti-Aging Medicine (A4M) Anti-Aging Therapeutics, Volume Xl;2009
http://www.lookfordiagnosis.com/videos.php?title=Coming+Pandemic+of+Liver+Cancer%3A+In+Search+of+Genomic+Solutions+-+Stanislaw+R.+…&content=Stanislaw+R.+Burzynski%2C+MD%2C+PhD+speaks+about+the+Coming+Pandemic+of+Liver+Cancer%3A+In+Search+of+Genomic+Solutions+at+16th+A4M+Conference+in+Las+…&lang=1

2009
http://www.aminocare.com/assets/pdf/Practical-application-of-gene-silencing-Volume-XI.pdf
Burzynski, S.R_
Practical application of gene silencing theory of aging
Life extension in animal testing and human clinical trials
In: American Academy ofAnti-Aging Medicine (A4M) Anti-Aging Therapeutics, Volume Xl ; 2009
http://www.a4minfo.net/Thera11.pdf

2008

Patil, S., Burzynski, S., Chittur, S., Mrowczynski, E., Grela, K.
The ingredients of antineoplaston AS2-1 down-regulate glycolysis pathways in glioblastoma cells
Neuro-Oncology 2008;10:1148

2008
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2719003
Burzynski, S., Weaver, R., Janicki, T., Szymkowski, B., Burzynski, G.
Phase II study ofantineoplastons A10 and AS2-1 infusions (ANP) in patients with recurrent anaplastic astrocy1oma
Neuro-Oncology 2008;10:1067

2008

Patil, S., Burzynski, S., Chittur, S., Mrowczynski, E., Grela, K.
Antineoplaston AS2-1 affects cell cycle checkpoints, leading to apoptosis in human glioblastoma cells
Neuro-Oncology 2008;10:786

2008
http://europepmc.org/articles/PMC2666253
Burzynski, S., Weaver, R., Janicki, T., Burzynski, G., Samuel, S., Szymkowski, B.
Phase II study of antineoplastons A10 and AS2-1 (ANP) in patients with newly diagnosed anaplastic astrocy1oma:
A preliminary report
Neuro-Oncology 2008; 10:821

2008
http://www.burzynskiresearch.com/assets/PressRelease_05062009_BZYR.pdf
Burzynski, S.R., Weaver, R., Janicki, T., Walczak, M., Szymkowski, B., Samuel, S.
Phase II study of antineoplastons A 10 and AS2-1 (ANP) in children with optic pathway glioma:
A preliminary report
Neuro-Oncology 2008;10:450

2008

Burzynski, S.R.
The genes of life
Farmapress Publishers, 2008

2008
http://www.aminocare.com/assets/pdf/The-Genetic-Approach-to-Cancer-Treatment-2008.pdf
Burzynski, S.R.
Genomic approach to cancer treatment
In: American Academy ofAnti-Aging Medicine (A4M)
Anti-Aging Therapeutics, Volume X; 2008;37-44

2007
http://www.cancer-therapy.org/CT/v5/A/42._Burzynski,_379-390.pdf
Burzynski, S.R.
Recent clinical trials in diffuse intrinsic brainstem glioma
Cancer Therapy 2007;5, 379-390

2007
http://europepmc.org/articles/PMC1994106
Burzynski, S.R., Weaver, R., Szymkowski, B.
A case report of a complete response and 20-year survival of a patient with a recurrent diffuse intrinsic brainstem anaplastic astrocytoma
Neuro-Oncology 2007;9:536

2007
http://europepmc.org/articles/PMC1994106
Patil, S., Burzynski, S.R., Mrowczynski, E., Grela, K.
Phenylacetylglutamine (PG) and phenylacetate (PN) interact additively to produce detachment-induced apoptosis/anoikis in glioblastoma cells
Neuro-Oncology 2007;9:482

2007
http://www.aminocare.com/assets/pdf/Publication_chapt%2010_AA%20Therapt%20Vol%20IX_2007.pdf
Burzynski, S.R.
The Genetic Solution forAnti-Aging
In: American Academy ofAnti-Aging Medicine (A4M) Anti· Aging Therapeutics, Volume IX; 2007;63-70

2007
http://www.aminocare.com/assets/pdf/Presentation_Chicago_July%202006.pdf
Burzynski, S.R.
Genetics of Brain Aging (1)
Gene Silencing in Neurons
In: American Academy ofAnti-Aging Medicine (A4M) Anti-Aging Therapeutics, Volume IX; 2007;71-78.

2007
http://www.aminocare.com/assets/pdf/Publication_chapt%2012_AA%20Therapt%20Vol%20IX_2007.pdf
Burzynski, S.R.
Genetics of Brain Aging (II)
Genetic Mechanisms in Encoding and Consolidation of Memory
In:

2007

Burzynski. S.R.• Weaver. RA. Janicki. T.J.•Jurida, G.F., Szymkowski. B.G.• Kubove. E.
Phase II studies of Antineoplastons A 10 and AS 2-1 (ANP) in children with newly diagnosed diffuse intrinsic brainstem gliomas
Neuro-Oncology 2007;9:206
http://doubtfulnews.com/wp-content/uploads/2011/11/pressrelease.pdf

2007

Burzynski. S.R.
The breakthrough in therapy and prevention in medicine of 21st century (5)
Genes and aging of the neurons
Geny a starzenie neuronow. Czasopismo Aptekarskie 2007; Nr 3 (159) 27-38

2007

Burzynski. S.R.
The breakthrough in therapy and prevention in medicine of 21st century (4)_
Time factor in biology and medicine
Czynnik czasu w biologii i medycynie. Czasopismo Aptekarskie 2007; Nr 2 (158) 27-36

2007

Burzy nski, S.R.
The breakthrough in therapy and prevention in medicine of 21st century (3)
The medicine of aging population
Medycyna starzejacego sie spoleczenstwa. Czasopismo Aptekarskie 2007; Nr 1 (157) 39-48

2006
https://www.novapublishers.com/catalog/product_info.php?products_id=5367
Burzynski, S.R.
Targeted Therapy for Brain Tumors
Columbus F, ed. Brain Cancer Therapy and Surgical Interventions. New York (NY); Nova Science Publishers, Inc. 2006;77-111

2006

Burzynski, S.R.
The breakthrough in therapy and prevention in medicine of 21st century (2)
Epigenome and gene silencing. Epigenom i wyciszanie genow. Czasopismo Aptekarskie 2006;Nr 12 (156) 29-36

2006

Burzynski, S.R.
The breakthrough in therapy and prevention in medicine of 21st century (1)
The medicine of genome an epigenome
Medycyna genomu i epigenomu. Czasopismo Aptekarskie 2006;Nr 11 (155) 45-52

2006
https://www.novapublishers.com/catalog/product_info.php?products_id=4028
Burzynski, S.R.
Age Management Treatments Which Target Silenced Genes
Redberry GW, ed. Gene Silencing: New Research. Nova Science Publishers, Inc. 2006

2006

Burzynski, S.R., Janicki, T.J., Weaver, RA, Szymkowski, B.G., Khan, M.L, Dolgopolov, V.
Treatment of multicentric brainstem gliomas with antineoplastons (ANP) A 10 and AS2-1
Neuro-Oncology. 2006;10:466

2006

Burzynski. S.R.•Weaver. RA. Szymkowski. B., Janicki. T.J.• Khan, M.L. Dolgopolov. V.
Complete response of a diffuse intrinsic brainstem tumor and von Hippel Lindau (VHL) disease to antineoplastons A 10 and AS2-1 (ANP):
a case report
Neuro-Oncology. 2006;10:439

2006
http://www.ncbi.nlm.nih.gov/m/pubmed/16774296
Burzynski. S.R.
Treatments for Astrocytic Tumors in Children:
Current and Emerging Strategies
Pediatric Drugs 2006;8:167-178
http://link.springer.com/article/10.2165%2F00148581-200608030-00003

2006
http://www.ncbi.nlm.nih.gov/m/pubmed/16484713
Burzynski. S.R., Janicki. T.J.•Weaver. RA, Burzynski, B.
Targeted therapy with AntineoplastonsA10 and AS2-1 of high grade, recurrent. and progressive brainstem glioma
Integrative Cancer Therapies 2006; 5(1):40-47
http://ict.sagepub.com/content/5/1/40.abstract
Integr Cancer Ther. 2006 Mar;5(1):40-7
http://m.ict.sagepub.com/content/5/1/40.short

2006

Burzynski, S.R., Weaver, RA, Janicki, T.J., Szymkowski, B.G., Jurida, G.F., Burzynski, B.
Phase II studies of antineoplastons A 10 and AS2-1 (ANP) in patients with recurrent, diffuse intrinsic brain stem gliomas
Neuro-Oncology 2006;10:346_

2006
http://www.aminocare.com/assets/pdf/Publication_Master%20Clock%20II_AA%20Therapt%20Vol%20VIII_2006.pdf
Burzynski, S.R.
Master Clock of Life (II)
How to Turn the Clock Back
In: American Academy ofAnti-Aging Medicine. American Academy ofAnti-Aging Medicine (A4M) Anti-Aging Therapeutics;Volume VIII 2006
http://www.a4minfo.net/Thera9.pdf

2006

Burzynski, S.R.
Master Clock of Life (1)
“Junk DNA.” and Promoters Regions as Major Components ofthe Clock
American Academy ofAnti-Aging Medicine (A4M) Anti-Aging Therapeutics;Volume VIII 2006

2005
http://www.aminocare.com/assets/pdf/Publication_Master%20Clock%20II_AA%20Therapt%20Vol%20VIII_2006.pdf
Burzynski, S. R.
Gene silencing theory of aging:
the clinical trial supporting the theory
Anti-Aging Therapeutics 2005;Vol Vll:39-46
http://www.a4m.com/assets/pdf/bookstore/aamt_vol7_toc.pdf?SESSION_MAIN=rhu6d1mfnjhkon8865nciot5v2

2005

Burzynski, S.R.,Weaver, RA,Janicki,T.J., Burzynski, B.,Jurida, G.
TargetedtherapywithANP inchildren less than 4 years old with inoperable brain stem gliomas
Neuro-Oncology 2005;7:300

2005

Weaver, RA , Burzynski, S.R., Janicki, T.J., Burzynski, B., Jurida, G., Szymkowski, B.
Long-term survival in patients with glioblastoma multiforme treated in phase II studies with ANP
Neuro-Oncology 2005;7:299

2005
http://ict.sagepub.com/content/4/2/168.abstract
Burzynski, S.R., Weaver. RA, Janicki, T.• Szymkowski, B., Jurida, G.• Khan, M.• Dolgopolov, V.
Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with Antineop!astons A 10 AS2-1
Integrative CancerTherapies 2005;4(2):168-177

2005
http://www.ncbi.nlm.nih.gov/m/pubmed/15533642
Burzynski. S.R.
Aging: Gene silencing or gene activation?
Med Hypoth 2005; 64, 201-208
http://www.medical-hypotheses.com/article/S0306-9877(04)00376-7/abstract
Med Hypotheses. 2005;64(1):201-8
http://www.medical-hypotheses.com/article/S0306-9877(04)00376-7/references

http://www.sciencedirect.com/science/article/pii/S0306987704003767

http://www.journals.elsevierhealth.com/periodicals/ymehy/article/PIIS0306987704003767/abstract

http://www.journals.elsevierhealth.com/periodicals/ymehy/article/S0306-9877(04)00376-7/abstract
PDF:
http://www.aminocare.com/assets/pdf/Publication_Gene%20Silencing%20or%20Gene%20Activation_Med%20Hypoth%202005.pdf
References:
http://www.medical-hypotheses.com/article/S0306-9877(04)00376-7/references

2004

Burzynski. S.R.
Mechanizmy i profilaktyka genetycznego starzenia. Mechanisms and prevention of genetic aging
Neurologia I Psychiatria 2004;4:1-8

2004
http://www.iaacn.org/Jan_54-1.pdf
Burzynski, S.R., llkowska-Musial, E., Klimczak M.W., Musial. L
Antineoplastons In Dairy Products
Journal of
Applied Nutrition 2004;54;1-8

2004

Burzynski, S.R., Weaver, R. Sestak. M., Lewy, R.L, Janicki, T., Jurida, G., Szymkowski, B., Khan, M., Dolgopolov, V.
Long-term survivals in phase II studies ofAntineoplastons A10 and AS2-1 (ANP) in patients with diffuse intrinsic brain stem glioma
Neuro-Oncology 2004;6:386

2004

Weaver, RA, Burzynski, S.R., Sestak, M., Lewy, R.L, Janicki, T.J., Szymkowski, B., Jurida, G., Khan, M.L, Dolgopolov, V.
Phase II study ofAntineoplastons A10 and AS2-1 (ANP) in recurrent glioblastoma multiforme
Neuro-Oncology 2004;6:384

2004

Burzynski, S.R., Weaver, R. Sestak. M., Janicki, T., Szymkowski, B., Jurida, G., Khan, M., Dolgopolov, V.
Treatment of primitive neuroectodermal tumors (PNET) with antineoplastons A 10 and AS2-1 (ANP)
Preliminary results of phase II studies
Neuro-Oncology 2004;6:428

2004

Burzynski, S.R., Weaver, R. Sestak. M., Janicki, T., Jurida, G., Szymkowski, B., Khan, M., Dolgopolov, V.
Phase II studies of antineoplastons A 10 and AS2-1 (ANP) in children with atypical teratoid/rhabcoid tumors (AT/RT) ofthe central nervous system. A preliminary report. Neuro-Oncology 2004;6:427

2004
http://www.ncbi.nlm.nih.gov/m/pubmed/15312271
Burzynski, S.R., Lewy, R.L, Weaver, R., Janicki, T., Jurida, G., Khan, M., Larisma, C.B., Paszkowiak, J., Szymkowski, B.
Long-term survival and complete response of a patient with recurrent diffuse intrinsic brain stem glioblastoma multiforme
Integrative Cancer Therapies 2004;3:257-261
http://ict.sagepub.com/content/3/3/257.abstract
Integr Cancer Ther. 2004 Sep;3(3):257-61
http://m.ict.sagepub.com/content/3/3/257.short

2004
http://www.ncbi.nlm.nih.gov/m/pubmed/15563234
Burzynski, S.R., Weaver, R., Lewy, R., Janicki, T. Jurida, G., Szymkowski, B., Khan, M., Sestak, M.
Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma
A Preliminary Report
Drugs R&D 2004;5(6):315-326
http://www.ingentaconnect.com/content/adis/rdd/2004/00000005/00000006/art00002
Drugs R D. 2004;5(6):315-26

2004
http://www.ncbi.nlm.nih.gov/m/pubmed/15035876
Burzynski, S.R.
The Present State ofAntineoplaston Research
Integrative Cancer Therapies 2004;3:47-58
http://ict.sagepub.com/content/3/1/47.abstract
Integr Cancer Ther. 2004 Mar;3(1):47-58
http://ict.sagepub.com/content/3/1/47.short

2003
http://www.ncbi.nlm.nih.gov/m/pubmed/12718563
Burzynski. S.R.• Lewy, R.L, Weaver. RA. Alder. M.L. Janicki. T.J.•Jurida, G.F., Paszkowiak. JK, Szymkowski. B.G.• Khan. M.L, Sestak, M.
Phase II Study ofAntineoplastons A10 and AS2-1 in Patients with
Phase II study of antineoplaston

A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report
http://www.ingentaconnect.com/content/adis/rdd/2003/00000004/00000002/art00002
Drugs R D. 2003;4(2):91-101

2003

W aldbillig R. Burzynski SR. Mechanism of action. uptake. and gene array studies on the antineoplastic agent phenylacetylglutamine (PG) in human glioma cells U-87
Neuro-Oncology 2003;10:309

2003

Burzynski. S.R.• W eaver. R A . Sestak. M.• Lewy, R.I.. Janicki. T.J.• Jurida. G.F.• Paszkowiak. J.K.. Szymkowski. B.G.• Khan. M.l.
Phase II study ofAntineoplastons A10 and AS2-1 (ANP) in children with recurrent and progressive multicentric glioma
A preliminary report
Neuro-Oncology 2003;10:3S8

2003
http://www.scribd.com/mobile/doc/26344902
Burzynski. S.R.
The Methylation Control of Gene Activation and Silencing Theory
The Basic Principles and Practice ofAnti-Aging Medicine & Age Management for the Aesthetic Surgeon and Physician
Vincent C. Giampapa (Ed.) 2003;33-4

2003

Burzynski, S.R., Maxwell L. Axler, Robert I. Lewy, Tomasz Janicki, Elwira llkowska-Musial. Anna Baranowska. M.Sc.
Amino Acid Supplementation in Treatment of Cancer-Related Symptoms
Journal ofApplied Nutrition 2003; S3:S2-60

2003
http://www.ncbi.nlm.nih.gov/m/pubmed/12615527
Burzynski, S. R.
Gene Silencing – A New Theory ofAging
Med Hypoth 2003; 60:S78-S83
http://www.medical-hypotheses.com/article/S0306-9877(03)00050-1/abstract
Med Hypotheses. 2003 Apr;60(4):578-83
References:
http://www.medical-hypotheses.com/article/S0306-9877(03)00050-1/references

2002

Burzynski, S.R.
Antineoplaston Therapy
Chapter in Integrative Oncology – Conventional and Complementary
Strategies
Urban & Fischer; 2002

2000

Burzynski, S.R.
Antineoplastons
In: Clinician’s Complete Reference To Complementary/Alternative Medicine,
Novey, D. W. (Ed.). Mosby 2000;496-S07, St.Louis, USA

2000

Burzynski, S.R.
The Best ofAlternative Medicine
Townsend Letter for Doctors 2000;200:32

1999
http://www.ingentaconnect.com/content/adis/cdi/1999/00000018/00000001/art00001?crawler=true
Burzynski, S.R., Conde, A.B.• Peters, A., Saling B., Ellithorpe, R., Daugherty , J.P., and Nacht C.H.
A Retrospective Study ofAntineoplastons A10 and AS2-1 in Primary Brain Tumors
Clin. Drug Invest 1999;18:1-10

1999
http://www.ncbi.nlm.nih.gov/m/pubmed/10377942
Burzynski. S.R.
Efficacy of Antineoplastons A 10 and AS2-1
Mayo Clin. Proc 1999;74:641-643
http://www.sciencedirect.com/science/article/pii/S0025619611641438
References:
http://www.mayoclinicproceedings.org/article/S0025-6196(11)64143-8/references

1998

Burzynski. S.R.
Antineoplastons in the treatment of malignant brain tumors
Anti-Aging Medical Terapeutics. vol.
2. Klatz RM.• Goldman R. (Ed)
Health Quest Publications 1998;28-34. Marina del Rey, Ca. USA

1997

Burzynski. S.R.
Antineoplastons. oncogenes and cancer
Anti-Aging Medical Therapeutics, Vol.1. Klatz RM.
Goldman R. (Ed)
Health Quest Publication 1997; Marina del Rey, CA. USA

1995
http://www.ncbi.nlm.nih.gov/m/pubmed/8535046
Burzynski, S.R.
Potential of antineoplastons in diseases of old age
Drugs & Aging 199S;7:1S7-167
http://link.springer.com/article/10.2165/00002512-199507030-00001?no-access=true
Drugs Aging. 1995 Sep;7(3):157-67

1995

Soltysiak-Pawluczuk, D., Burzynski, S.R., Feldo, M., Majewska, B., Kleinrok, Z.
Cellular accumulation of antineoplaston AS2-1 in human hepatoma cells
Cancer Letters 88 (1995);88:107-112

1995
http://www.ncbi.nlm.nih.gov/m/pubmed/8529528
Juszkiewicz, M., Chodkowska, A., Burzynski, S.R., Mlynarczyk, M., Kleinrok, Z.
The influence of antineoplaston AS on particular subtypes of central dopaminergic receptors
Drugs Exptl Clin Res 199S;21:1S3-1S6
http://journals.indexcopernicus.com/abstracted.php?icid=615614
Drugs Exp Clin Res. 1995;21(4):153-6

1994
http://www.ncbi.nlm.nih.gov/m/pubmed/7813388
Juszkiewicz, M., Chodkowska, A., Burzynski, S.R., Feldo, M., Majewska, B., Kleinrok, Z.
The influence of antineoplaston AS on the central dopaminergic structures
Drugs Exptl Clin Res 1994;20:161-167
http://journals.indexcopernicus.com/abstracted.php?icid=615613
Drugs Exp Clin Res. 1994;20(4):161-7

1993

Burzynski, S.R.
lmmunosurveillance versus chemosurveillance
Post Nauk Med 1993;6:260-262

1993

Burzynski. S.R.
Antineoplastons
An Investigational CancerTherapy
Townsend Letter for Doctors 1993;3,1S0-1S3

1992

Burzynski. S.R.
Novel differentiation inducers
Recent Advances in Chemotherapy
Adam D. (Ed). Futuramed
Publishers. 1992; Munich. Germany

1992

Liau. M.C.• Liau. C.P.• Burzynski. S.R.
Potentiation of induced terminal differentiation by phenylacetic acid and related chemicals
lnternat J Exptl Clin Chemother 1992;S:9-17

1992

Liau, M.C., Luong, Y., Liau, C.P., Burzynski, S.R.
Prevention of drug induced DNA hypermethylation by antineoplaston components
Internal J Exptl Clin Chemother 1992;S:19-27

1992

Lee, S.S., Bu rzynski, S.R.
Synergistic Effect of Antineoplaston A S and Retinoic Acid on the Induction of Human Promyelocytic Leukemia line HL-60
Recent Advances in Chemotherapy
Adam D. (Ed), Futuramed Publishers. 1992: Munich, Germany

1992

Liau, M.C., Luong, Y., Liau, C.P., Burzynski, S.R.
Prevention of drug-induced DNA hypermethylation by antineoplastons
Recent Advances in Chemotherapy
Adam D. (Ed), Futuramed Publishers. 1992; Munich, Germany

1992

Burzynski , S.R , Kubove , E., Burzynski, B.
Phase II clinical trials of antineoplastons A10 and AS 2- 1 infusions in astrocytoma
Recent Advances in Chemotherapy
Adam D. (Ed), Futuramed Publishers. 1992; Munich, Germany

1991

Lee, S.S., Burzynski, S.R. Antineoplaston AS:
A growth inhibitor for cancerous cells and growth stimulator for normal cells
Internal J Exptl Clin Chemother 1991;4:63-6S

1990

Kampalath, B.N., Liau, M.C., Burzynski, B., Burzynski, S.R.
Protective effect ofantineoplaston A10 in hepatocarcinogenesis induced by aflatoxin 81
Internal J Tissue Reactions 1990;12 (supp1):43-SO

1990

Liau, M.C., Lee, S.S., Burzynski, S.R
Modulation of cancer methylation complex isoenzymes as a decisive factor in the induction of terminal differentiation mediated by antineoplaston A5
Internat J Tissue Reactions 1990; 12 (suppl): 27-36

1990

Lee, S.S.• Burzynski. S.R.
Inducibility of HL-60 leukemic cells to undergo terminal differentiation after repeated treatment with antineoplaston A5
Internat J Exptl Clin Chemother 1990;3:12S-128

1990

Lee, S.S.• Burzynski. S.R.
Induction ofdifferentiation of HL-60 human promyelocytic leukemic cell by antineoplaston A5
Internal J Tissue Reactions 1990;12(suppl):37-42

1990

Liau, M.C.• Ashraf. A.a.. Lee. S.S.• Hendry, L.B., Burzynski. S.R.
Riboflavin as a minor active anticancer component of antineoplaston A2 and A5
Internal J Tissue Reactions 1990;12:19-26

1990

Liau, M.C., Lee, S.S., Burzynski, S.R.
Separation of active anticancer components of antineoplaston A2, A3, and A5
Internat J Tissue Reactions 1990; 12 (suppl): 1-17

1990
http://www.ncbi.nlm.nih.gov/m/pubmed/2152694
Burzynski, S.R., Kubove, E., Burzynski, B
Treatment of hormonally refractory cancer ofthe prostate with antineoplaston AS2-1
Drugs Exptl Clin Res 1990;16: 361-369
Drugs Exp Clin Res. 1990;16(7):361-9

Burzynski, S.R.
Isolation, purification and synthesis of antineoplastons
Internal J Exptl Clin Chemother

l~tl~;;!:b:J-b~-

l~tl~;;!:b:J-b~

1989

Liau, M.C., Lee, S.S., Burzynski, S.R
Hypomethylation of nucleic acids:
A key to the induction of terminal
differentiation
Internal J Exptl Clin Chemother 1989;2:187-199

1988

Hendry, LB., Muldoon, T.G., Burzynski, S.R
Modeling studies suggest the modified dipeptide analog
phenylacetylamino-2, 6-piperidinedione may interact with DNA
Adv Exptl Clin Chemother. 1988; 2: 11-13.

1988

Burzynski, S.R
Antineoplastons:
Basic research and clinical applications
Adv Exptl Clin Chemother_1988; 2:
1-9_

1988

Burzynski, S.R
Isolation, purification and synthesis of antineoplastons
Adv Exptl Clin Chemother_1988; 6: 1-7_

1988

Liau, M.C., Lee, S.S, Burzynski, S.R
Differentiation inducing components of antineoplaston A5
Adv Exptl Clin Chemother. 1988; 6: 9-2S

1988

Lee, S.S ., Burzy nski, S R
Terminal differentiation of HL-60 human promyelocytic leukemia cells induced by antineoplaston A2
Adv Exptl Clin Chemother 1988;6:27-31

1988

Burzynski, S.R.
Treatment of bladdercancer with antineoplaston formulations
Adv Exptl Clin Chemother. 1988. 2: 37-46

1988

Burzynski, S.R., Kubove, E ., Burzynski, B.
Phase I clinical studies of oral formulation of antineoplaston AS2-1
Adv Exptl Clin Chemother 1988;2:29-36

1988

Burzynski, S.R.
Treatment of malignant brain tumors with antineoplastons
Adv Exptl Clin Chemother 1988;6:45- 56

1988

Ashraf, AQ., Kampalath, B.N., Burzynski, S.R
Pharmacokinetic analysis of antineoplaston A10 injections following intravenous administration in rats
Adv Exptl Clin Chemother 1988;6:33-39

1988

Ashraf, AQ.,Burzynski, S.R.
Comparative study of antineoplaston A10 levels in plasma of healthy people and cancer patients
Adv Exptl Clin Chemother 1988;2 : 19-28

1987

Lee, S.S., Burzynski, S.R
Tissue culture and animal toxicity studies of antineoplaston AS
Drugs Exptl Clin Res 1987;13 (suppl 1):31-3S_

1987

Kampalath, B.N., Liau, M.C., Burzynski, B., Burzynski, S.R.
Chemoprevention by antineoplastonA10 ofbenzo (a) pyrene-induced pulmonary neoplasia
Drugs Exptl Clin Res 1987;13 (suppl 1):S1-SS_

1987

Liau, M.C., Szopa, M., Burzynski, B., Burzynski, S.R
Chemoswveillance:
A novel concept of the natural defense mechanism against cancer
Drugs Exptl Cline Res 1987;13 (suppl 1):71-76

1987

Lee, S.S., Mohabbat, M.O., Burzynski, SR
In vitro cancergrowth inhibition and animal toxicity studies of antineoplaston A3
Drugs Exptl Clin Res 1987;13 (suppl1):13-16

1987

Khalid, M., Burzynski, S.R.
N,N’-<Jisubstituted L-isoglutamines as novel cancer chemotherapeutic agents
Drugs Exptl Clin Res 1987;13 (suppl 1):S7-60

1987

Hendry, LB., Muldoon, T.G., Burzynski, S.R., Copland, JA, Lehner, A.F.
Stereochemical modeling studies of the interaction of antineoplaston A 10 with DNA
Drugs Exptl Clin Res 1987;13 (suppl 1):77-81

1987

Burzynski, S.R., Kubove, E .
Initial clinical study with antineoplaston A2 injections in cancer patients with five years follow-up
Drugs Exptl Clin Res 1987;13 (suppl1):1-12

1987

Burzy nski, S.R., Kubove, E .
Phase I clinical studies of antineoplaston A3 inJections_
Drugs Exptl Clin Res 1987;13 (suppl 1):17-29

1987

Burzynski, S.R., Kubove, E., Burzynski, B.
Phase I clinical studies of antineoplaston AS injections_
Drugs ExptL Clin Res 1987;13 (suppl 1):37-43

1987

Liau, M.C., Szopa, M., Burzynski, B., Burzynski, S.R_
Quantitative assay of plasma and urinary peptides as an aid for the evaluation ofcancer patients undergoing antineoplaston therapy.
Drugs Exptl Clin Res 1987;13 (suppl 1) :6 1-7 0

1987

Ashraf, A Q., Liau, M.C., Kampalath, B.N., Burzynski, S.R
Pharmacokinetic study of radioactive antineoplaston A10followingoraladministrationinrats_
DrugsExptlClinRes 1987;13(suppi1):4S-SO_

1986

Burzynski, S.R., Mohabbat M_Q_
Chronic animal toxicity studies of antineoplaston A2.
Drugs Exptl Clin Res 1986;12 (suppl 1):73-7S_

1986

Ashraf, AQ., Liau, M.C., Mohabbat, M.O., Burzynski, S.R_
Preclinical studies ofantineoplastonA10 injections_
Drugs Exptl Clin Res 1986;12 (suppl 1):37-4S_

1986

Burzynski, S. R. , Mohabbat, M. O. , Le e, s _s _ Pre clinical studies of antineoplaston AS2-1 and antineoplaston AS2-S
Drugs Exptl Clin Res 1986;12 (suppl1):11-16

1986

Burzynski, S.R.
Antineoplaston A3
Drugs ofthe Future 1986;11:SS1-SS2

1986

Burzynski, S.R.
Antineoplastons – History ofthe research (1)
Drugs Exptl Clin Res 1986;12 (suppl1):1-9

1986

Burzynski, S.R.
Antineoplaston AS2-5
Annual Drug Data Report 1986;8:319

1986

Burzynski, S.R.
Antineoplaston AS2-1
Annual Drug Data Report 1986;8:320

1986

Burzynski, S.R., Khalid, M_
Antineoplaston AS2-S
Drugs of the Future 1986;11:364-36S_

1986

Burzynski, S.R_
AntineoplastonA10injections_
Annual Drug Data Report 1986;8:S97_

1986

Burzynski, S.R_
Antineoplaston A3
Annual Drug Data Report 1986;8:4 12

1986

Burzynski, S.R.
Antineoplaston A2
Annual Drug Data Report 1986;8:S04

1986

Burzynski, S.R., Khalid, M.
Antineoplaston AS2-1
Drugs of the Future 1986; 11: 361-363

1986

Burzynski, S.R.
Antineoplaston A2
Drugs ofthe Future 1986;11:549-550

1986

Burzynski, S.R.
Antineoplaston AS
Annual Drug Data Report 1986;8:869

1986

Burzynski, S.R_
Antineoplaston AS
Drugs ofthe Future 1986;11:824-82S

1986

Burzynski, S.R_
Synthetic antineoplastons and analogs
Drugs ofthe Future 1986;11: 679-688

1986

Liau, M.C., Burzynski, S R
Altered methylation complex isoenzymes as selective targets for cancer chemotherapy
Druos Exotl Clin Res 1986:12 (suool 1\:77-86.

1986

Lehner, A.F., Burzynski, S.R., Hendry, L.B.
3-phenylacetylamino-2, 6-piperidinedione, a naturally occurring peptide analog with apparent antineoplastic activity may bind to DNA.
Drugs Exptl Clin Res 1986;12 (suppl 1):57-72

1986

Burzynski, S.R., Kubove, E.
Toxicology studies ofantineoplastonA10injections incancer patients
Drugs Exptl Clin Res 1986;12 (suppl 1):47-55

1986

Burzynski, S.R.
Toxicology studies of antineoplaston AS2-5 injections in cancer patients
Drugs Exptl Clin Res 1986;12 (suppl 1):17-24

1986

Burzynski, S.R., Burzynski, B., Mohabbat, M.O.
Toxicology studies of antineoplaston AS2-1 injections in cancer patients
Drugs Exptl Clin Res 1986;12 (suppl 1):25-35

1986

Burzynski, S., Mohabbar. M., Lee, S.
Preclinical studies of antineoplaston AS2-1 in mice with oral administration
Drugs Exptl Clin Res 1986;132

1985

Lee, S.S., Mohabbat, M.O., Burzynski, S.R.
Tissue culture and acute animal toxicity studies of antineoplaston A2
Future Trends in Chemotherapy 1985;6:481-484

1985

Burzynski, S.R., Hai TI.
Antineoplaston A10
Drugs of the Future 1985;10:103-105

1985

Burzynski, S.R.
Phase I clinical studies of antineoplaston AS2-5 injections
Recent Advances in Chemotherapy
lshigami J. (Ed). University ofTokyo Press. 1985; Tokyo, Japan

1985

Burzynski, S.R.• Mohabbat. M.O., Burzynski, B.
Toxicology studies on oral formulation of antineoplaston A 10 in cancer patients
Future Trends in Chemotherapy 1985;6:485-493

1984

Burzynski, S.R., Mohabbat MO, Burzynski B.
Animal toxicology studies on oral formulation of antineoplaston A10
Drugs Exptl Clin Res 1984;10:113-118

1984

Lee, S.S., Mohabbat, M.O., Burzynski, S.R.
Tissue culture and animal toxicity studies of antineoplaston A2
Drugs Exptl Clin Res 1984;10:607-610

1984

Burzynski,S.R.
Antineoplaston A10
AnnualDrugDataReport 1984;6:124

1984

Burzynski, S.R., Mohabbat, M.O., Burzynski, B.
Human toxicology studies on oral formulation of antineoplaston A10
Drugs Exptl Clin Res 1984;10:891-909

1984

Burzynski,S.R.,Mohabbat,M.O.,Burzynski,B.
Toxicology studiesonoralformulationofantineoplastonA10 in cancer patients
Drugs Exptl Clin Res 1984;10:611-619

1979

Beall, P., Szopa, B., Burzynski, S.R., Hazlewood, C.F.
Polypeptides that inhibit human breast cancer cell division
Cancer Biochem Biophys 1979;3:93-96

1978

Burzynski, S.R.
Antyneoplastony
Przeglad Lekarski 1978;6:583-586

1977

Gross S, Galicka N. Grabarczyk M. Giannini M. Burzynski SR. Stolzmann Z.
Urinary peptides inhibit DNA
synthesis in vitro in certain cultured neoplastic cells
Clin Chern 1977;23:148-149

1977

Burzynski, S.R., Stolzmann. Z., Szopa, B., Stolzmann. E., Kaltenberg, O.P.
Antineoplaston A in cancer therapy
(1)
Physiol Chern Phys 1977;9:485-500

1976

Burzynski, S.R.
Antineoplastons:
Biochemical defense against cancer
Physiol Chern Phys 1976;8:275-279

1976

Gross, S., Galicka, N., Burzynski, S.R., Stolzmann, A.
Urinary peptides in muscular dystrophy
Physiol Chern Phys 1976;8:161-166

1976

Burzynski, S.R
Sequential analysis in subnanomolar amounts of peptides; Determination of the structure of a habituation-induced brain peptide (ameletin)
Anal Biochem 1976;70:359-365

1976

Burzynski, S.R., Lao, T.L., Ho, D.H., Rao, P.N., Georgiades, J., Kratzenstein, H.
Biologically active peptides in human urine:
Ill. Inhibitors ofthe growth of leukemia, osteosarcoma and HeLa cells
Physiol Chern Phys 1976;8: 13-22

1976

Burzynski, S.R., Rao, P.N., Gross, S., Stolzman, Z.
lnhibition of the Growth ofHeLa Cells bythe Peptide Isolated from Normal Human Urine
Fed Proc 1976;35:623

1975

Burzynski. S.R.
Quantitative analysis of amino acids and peptides in the femtomolar range
Anal Biochem 1975;65:93-99

1975

Burzynski. S.R.. Ungar. G.
Brain Peptides Associated with Habituation to a Sound Stimulus
Neuroscience Abstracts 1975;1:329

1975

Ungar. G., Burzynski, S.R.• Tate. D.L.
Learning-induced Brain Peptides
Peptides:
Chemistry, structure and biology
Walter. R., Meienhofer. J. (Ed). Ann Arbor Science; 1975; Ann Arbor. Michigan. USA

1974

Burzynski, S.R., Ungar, A.L., Lubanski, E.
Biologically active peptides in human urine:
II. Effect on intestinal smooth muscle and heart
Physiol Chern Phys 1974;6:457-468

1974

Burzynski, S.R., Ungar, A.L., Lubanski, E.
Effect of Urinary Peptides on Smooth Muscle and Heart
Fed Proc 1974;33:547

1973

Burzynski, S.R.
Biologically active peptides in human urine:
L Isolation of a group of medium-sized peptides
Phy siol Chern Phy s 1973;5:437-447
1973 – Biologically active peptides in human urine
I. Isolation of a group of medium-sized peptides
http://www.ncbi.nlm.nih.gov/m/pubmed/4775589
S R Burzynski
Physiol Chem Phys 5(5):437-47 (1973), PMID .4775589
Cited by:
5/1992 – 4) – Japan – Tsuda
Jpn. J. Cancer Res. 83, 527-531
1988 – – A10 – Hendry & Muldoon – J rSteroid Biochem. 1988;30(1-6):325-8

1973

Burzynski, S.R., Georgiades, J.
Effect of Urinary Peptides on DNA, RNA and Protein Synthesis in Normal and Neoplastic Cells
Fed Proc 1973;32:766

1973

Ungar, G., Burzynski, S.R
Isolation and Purification of a Habituation-inducing Peptide from Trained Rat Brain
Fed Proc 1973;32:367

1970

Burzynski , S., Czerniak, Z.
A simple method for the separation of free and bound amino acids and its application to the identification of bound amino acids in human blood serum
Chern Anal 1970;15:223-225
__________________________
1970 – Burzyński S
http://www.ncbi.nlm.nih.gov/m/pubmed/5531748
[Free amino acids in serum of obese children]
Endokrynol Pol. 1970;21(6):611-7. Article in Polish
1970
Szajner-Milart, J., Burzynski. S.R . Paczos-Chadyma. E.. Czerniak, Z.
Free amino acids in serum of obese children
Endokr Pol 1970;21:611-617

1969

Krzeczkowska, 1., Czerniak, Z.. Burzynski. S.
Quantitative determinations of carbohydrates and their statistical analysis
L Results obtained in various conditions using paper and thin-layer chromatography
Chern Anal
1969; 1 3 : 1221-1228

1969

Burzynski. S.
Investigations on unknown ninhydrin-reacting substances in human blood serum L Attempts at identification ofthree such substances
Experientia 1969;25:490-491

1969
http://www.ncbi.nlm.nih.gov/m/pubmed/5801388
Burzynski. S.
Bound amino acids in serum of patients with chronic renal insufficiency
Clin Chim Acta 1969;25:231 -237
http://www.sciencedirect.com/science/article/pii/0009898169902599
Clin Chim Acta. 1969 Aug;25(2):231-7
Clinica Chimica Acta
Volume 25, Issue 2, August 1969, Pages 231–237
__________________________
8/1969 – Burzyński S
http://www.ncbi.nlm.nih.gov/pubmed/5801388
Clin Chim Acta. 1969 Aug;25(2):231-7

1969
http://www.ncbi.nlm.nih.gov/m/pubmed/5797414
Czerniak, Z., Burzynski, S.
Free amino acids in serum of patients with chronic renal insufficiency
Clin Chim Acta 1969;24:367-372
http://www.sciencedirect.com/science/article/pii/0009898169901077
Clin Chim Acta. 1969 Jun;24(3):367-72
Clinica Chimica Acta
Volume 24, Issue 3, June 1969, Pages 367–372
__________________________
6/1969 – BURZYNSKI S
http://www.ncbi.nlm.nih.gov/pubmed/5797414
Clin Chim Acta. 1969 Jun;24(3):367-72
__________________________
5/1969 – BURZYNSKI S
http://www.ncbi.nlm.nih.gov/m/pubmed/5796158
Investigations on unknown ninhydrin-reacting substances in human blood serum
I. Attempts at identification of 3 such substances
Experientia. 1969 May 15;25(5):490-1

1969

Burzynski, S., Czerniak, Z.
A simple method for free and bound amino acid separation
Folia Soc Sci Lub 1969/70;Sec. A-D 9/10 (suppl):143-144

1969

Burzynski, S., Czerniak, Z.
Quantitative determination of amino acids using photometry of negative printed chromatograms
Modification of the method and its application for amino acid analysis in blood serum
Chern Anal 1969;14:667-671

1969

Czerniak, Z., Burzynski, S.
Qualitative analysis of amino acids using the multiple development of chromatograms in different eluents
Chem Anal 1969;14:673-676

1968

Krzeczkowska, L, Czerniak, Z., Burzynski, S.
Quantitative determinations of free amino acids in the blood of patients with myocardial infarction using a new method of photometry of the negative printed chromatograms
Pol Arch Med Wewn 1968;41:361-368

1968

Krzeczkowska, L, Czerniak, Z., Burzynski, S.
Quantitative determinations of free amino acids in human blood with the use of our own method and Beckman amino acid analyzer
Pol Arch Med W ewn 1968;40:223-228
__________________________
1968 – BURZYNSKI S
http://www.ncbi.nlm.nih.gov/m/pubmed/5669683
[Quantitative determination of amino acids in human blood with the use of our method and Beckman’s “amino acid analyser”]
Pol Arch Med Wewn. 1968;40(2):223-8. Article in Polish

1968

Krzeczkowska, L, Czerniak, Z.. Burzynski, S.
Quantitative determinations of carbohydrates and their statistical analysis, IL Analysis of variance for four-crossed classification and Tukey confidence intervals
Chern Anal 1968; 13: 1229-1238

1968

Burzynski. S.
Investigations on amino acids and peptides in blood serum of healthy people and patients with chronic renal insufficiency
1968; Lublin. Poland: 274 pp (doctoral dissertation)

__________________________
1966 – BURZYNSKI S
http://www.ncbi.nlm.nih.gov/m/pubmed/5996263
[The application of the photometry of negative printed chromatograms for quantitative determination of free amino acids in the blood of healthy people]
Ann Univ Mariae Curie Sklodowska Med. 1966;21:313-22. Article in Polish
1966
Krzeczkowska. 1., Czerniak. Z., Burzynski, S.
The application ofthe negative printed chromatograms for quantitative determination of free amino acids in the blood of healthy people
Ann Univ MC Sklodowska 1966; 2 1: 313-322

1966
http://www.ncbi.nlm.nih.gov/m/pubmed/5996246
Krzeczkowska. 1., Burzynski, S. Czerniak Z.
Quantitative determination of amino acids using photometry of negative printed chromatograms
Ann Univ MC Sklodowska 1966;21:125-134
Ann Univ Mariae Curie Sklodowska Med. 1966;21:125-34. Article in Polish

1965

Krzeczkowska, 1., Burzynski, S., Czerniak. Z.
Investigations on the possibility ofthe determination of mushroom species on the basis ofthe composition of their amino acids
Ann Univ MC Sklodowska 1965;20:221-229

1965

Krzeczkowska, L, Czerniak, Z., Burzynski, S.
Free and bound amino acids of some edible mushrooms
Ann Univ MC Sklodowska 1965;20:303-312

1964
http://www.ncbi.nlm.nih.gov/m/pubmed/5893108
Krzeczkowska, L, Czerniak, Z., Burzynski, S.
Bound amino acids of some edible mushrooms
Ann Univ MC Sklodowska 1964;19:329-336
Ann Univ Mariae Curie Sklodowska Med. 1964;19:329-36. Article in Polish

1964
http://www.ncbi.nlm.nih.gov/m/pubmed/5893107
Krzeczkowska, L, Burzynski, S., Czerniak, Z.
Free amino acids of some edible mushrooms
Ann Univ MC Sklodowska 1964;19:321-328
Ann Univ Mariae Curie Sklodowska Med. 1964;19:321-8. Article in Polish

1986

Lehner, A.F., Burzynski, S.R., Hendry, L.B.
3-phenylacetylamino-2, 6-piperidinedione, a naturally occurring peptide analog with apparent antineoplastic activity may bind to DNA
Drugs Exptl Clin Res 1986;12 (suppl 1):57-72

1986

Burzynski, S.R., Kubove, E.
Toxicology studies ofantineoplastonA10injections incancerpatients
Drugs Exptl Clin Res 1986;12 (suppl 1):47-55

1986

Burzynski, S.R.
Toxicology studies of antineoplaston AS2-5 injections in cancer patients
Drugs Exptl Clin Res 1986;12 (suppl 1):17-24

1986

Burzynski, S.R., Burzynski, B., Mohabbat, M.O.
Toxicology studies of antineoplaston AS2-1 injections in cancer patients
Drugs Exptl Clin Res 1986;12 (suppl 1):25-35

1986

Burzynski, S., Mohabbar. M., Lee, S.
Preclinical studies of antineoplaston AS2-1 in mice with oral administration
Drugs Exptl Clin Res 1986;132

1985

Lee, S.S., Mohabbat, M.O., Burzynski, S.R.
Tissue culture and acute animal toxicity studies of antineoplaston A2
Future Trends in Chemotherapy 1985;6:481-484

1985

Burzynski, S.R., Hai TI.
Antineoplaston A10
Drugs of the Future 1985;10:103-105

1985

Burzynski, S.R.
Phase I clinical studies of antineoplaston AS2-5 injections
Recent Advances in Chemotherapy.
lshigami J. (Ed). University ofTokyo Press. 1985; Tokyo, Japan

1985

Burzynski, S.R.• Mohabbat. M.O., Burzynski, B.
Toxicology studies on oral formulation of antineoplaston A 10 in cancer patients
Future Trends in Chemotherapy 1985;6:485-493

1984

Burzynski, S.R., Mohabbat MO, Burzynski B.
Animal toxicology studies on oral formulation of antineoplaston A10
Drugs Exptl Clin Res 1984;10:113-118

1984

Lee, S.S., Mohabbat, M.O., Burzynski, S.R.
Tissue culture and animal toxicity studies of antineoplaston A2
Drugs Exptl Clin Res 1984;10:607-610

1984

Burzynski,S.R.
AntineoplastonA10.AnnualDrugDataReport 1984;6:124

1984

Burzynski, S.R., Mohabbat, M.O., Burzynski, B.
Human toxicology studies on oral formulation of antineoplaston A10
Drugs Exptl Clin Res 1984;10:891-909

1984

Burzynski,S.R.,Mohabbat,M.O.,Burzynski,B.
Toxicology studiesonoralformulationofantineoplastonA10in cancer patients
Drugs Exptl Clin Res 1984;10:611-619

1979

Beall, P., Szopa, B., Burzynski, S.R., Hazlewood, C.F.
Polypeptides that inhibit human breast cancer cell division
Cancer Biochem Biophy s 1979;3:93-96

1978

Burzynski, S.R.
Antyneoplastony
Przeglad Lekarski 1978;6:583-586

1977

Gross S, Galicka N. Grabarczyk M. Giannini M. Burzynski SR. Stolzmann Z.
Urinary peptides inhibit DNA
synthesis in vitro in certain cultured neoplastic cells
Clin Chern 1977;23:148-149

1977

Burzynski, S.R., Stolzmann. Z., Szopa, B., Stolzmann. E., Kaltenberg, O.P.
Antineoplaston A in cancer therapy
(1)
Physiol Chern Phys 1977;9:485-500

1976

Burzynski, S.R.
Antineoplastons: Biochemical defense against cancer
Physiol Chern Phys 1976;8:275-279

1976

Gross, S., Galicka, N., Burzynski, S.R., Stolzmann, A.
Urinary peptides in muscular dystrophy
Physiol Chern Phys 1976;8:161-166

1976

Burzynski, S.R
Sequential analysis in subnanomolar amounts of peptides; Determination of the structure of a habituation-induced brain peptide (ameletin)
Anal Biochem 1976;70:359-365

1976

Burzynski, S.R., Lao, T.L., Ho, D.H., Rao, P.N., Georgiades, J., Kratzenstein, H.
Biologically active peptides in human urine:
Ill. Inhibitors ofthe growth of leukemia, osteosarcoma and HeLa cells
Physiol Chern Phys 1976;8: 13-22

1976

Burzynski, S.R., Rao, P.N., Gross, S., Stolzman, Z.
lnhibition of the Growth ofHeLa Cells bythe Peptide Isolated from Normal Human Urine
Fed Proc 1976;35:623

1975
http://www.ncbi.nlm.nih.gov/m/pubmed/1130705
Burzynski. S.R.
Quantitative analysis of amino acids and peptides in the femtomolar range
Anal Biochem 1975;65:93-99
http://www.sciencedirect.com/science/article/pii/0003269775904959
Anal Biochem. 1975 May 12;65(1-2):93-99
Analytical Biochemistry
Volume 65, Issues 1–2, 12 May 1975, Pages 93–99

1975

Burzynski. S.R.. Ungar. G.
Brain Peptides Associated with Habituation to a Sound Stimulus
Neuroscience Abstracts 1975;1:329

1975

Ungar. G., Burzynski, S.R.• Tate. D.L.
Learning-induced Brain Peptides
Peptides:
Chemistry, structure and biology
Walter. R., Meienhofer. J. (Ed). Ann Arbor Science; 1975; Ann Arbor. Michigan. USA

1974
http://www.ncbi.nlm.nih.gov/m/pubmed/4548759
Burzynski, S.R., Ungar, A.L., Lubanski, E.
Biologically active peptides in human urine:
II. Effect on intestinal smooth muscle and heart
Physiol Chern Phys 1974;6:457-468
Physiol Chem Phys. 1974;6(5):457-68

1974

Burzynski, S.R., Ungar, A.L., Lubanski, E.
Effect of Urinary Peptides on Smooth Muscle and Heart
Fed Proc 1974;33:547

1973
http://www.ncbi.nlm.nih.gov/m/pubmed/4775589
Burzynski, S.R.
Biologically active peptides in human urine:
L Isolation of a group of medium-sized peptides
Physiol Chern Phys 1973;5:437-447
Physiol Chem Phys. 1973;5(5):437-47

1973

Burzynski, S.R., Georgiades, J.
Effect of Urinary Peptides on DNA, RNA and Protein Synthesis in Normal and Neoplastic Cells
Fed Proc 1973;32:766

1973

Ungar, G., Burzynski, S.R
Isolation and Purification of a Habituation-inducing Peptide from Trained Rat Brain
Fed Proc 1973;32:367

1970

Burzynski , S., Czerniak, Z.
A simple method for the separation of free and bound amino acids and its application to the identification of bound amino acids in human blood serum
Chern Anal 1970;15:223-225

1970
http://www.ncbi.nlm.nih.gov/m/pubmed/5531748
Szajner-Milart, J., Burzynski. S.R . Paczos-Chadyma. E.. Czerniak, Z.
Free amino acids in serum of obese children
Endokr Pol 1970;21:611-617
Endokrynol Pol. 1970;21(6):611-7. Article in Polish

1969

Krzeczkowska, 1., Czerniak, Z.. Burzynski. S.
Quantitative determinations of carbohydrates and their statistical analysis
L Results obtained in various conditions using paper and thin-layer chromatography
Chern Anal
1969 ; 1 3 : 1221 – 1228

1969

Burzynski. S.
Investigations on unknown ninhydrin-reacting substances in human blood serum L Attempts at identification ofthree such substances
Experientia 1969;25:490-491

1969
http://www.ncbi.nlm.nih.gov/m/pubmed/5801388
Burzynski. S.
Bound amino acids in serum of patients with chronic renal insufficiency
Clin Chim Acta 1969;25:231 -237
http://www.sciencedirect.com/science/article/pii/0009898169902599
Clin Chim Acta. 1969 Aug;25(2):231-7
Clinica Chimica Acta
Volume 25, Issue 2, August 1969, Pages 231–237

1969
http://www.ncbi.nlm.nih.gov/m/pubmed/5797414
Czerniak, Z., Burzynski, S.
Free amino acids in serum of patients with chronic renal insufficiency
Clin Chim Acta 1969;24:367-372
http://www.sciencedirect.com/science/article/pii/0009898169901077
Clin Chim Acta. 1969 Jun;24(3):367-72
Clinica Chimica Acta
Volume 24, Issue 3, June 1969, Pages 367–372

1969

Burzynski, S., Czerniak, Z.
A simple method for free and bound amino acid separation
Folia Soc Sci Lub 1969/70;Sec. A-D 9/10 (suppl):143-144

1969
http://www.ncbi.nlm.nih.gov/m/pubmed/5996246
Burzynski, S., Czerniak, Z.
Quantitative determination of amino acids using photometry of negative printed chromatograms
Modification of the method and its application for amino acid analysis in blood serum
Chern Anal 1969;14:667-671
Ann Univ Mariae Curie Sklodowska Med. 1966;21:125-34. Article in Polish

1969

Czerniak, Z., Burzynski, S.
Qualitative analysis of amino acids using the multiple development of chromatograms in different eluents
Chem Anal 1969;14:673-676

1968

Krzeczkowska, L, Czerniak, Z., Burzynski, S.
Quantitative determinations of free amino acids in human blood with the use of our own method and Beckman amino acid analyzer
Pol Arch Med W ewn 1968;40:223-228

1968

Krzeczkowska, L, Czerniak, Z., Burzynski, S.
Quantitative determinations of free amino acids in the blood of patients with myocardial infarction using a new method of photometry of the negative printed chromatograms
Pol Arch Med Wewn 1968;41:361-368

1968

Krzeczkowska, L, Czerniak, Z.. Burzynski, S.
Quantitative determinations of carbohydrates and their statistical analysis, IL Analysis of variance for four-crossed classification and Tukey confidence intervals
Chern Anal 1968; 13: 1229-1238

1968

Burzynski. S.
Investigations on amino acids and peptides in blood serum of healthy people and patients with chronic renal insufficiency
1968; Lublin. Poland: 274 pp (doctoral dissertation)

1966
http://www.ncbi.nlm.nih.gov/m/pubmed/5996246
Krzeczkowska. 1., Burzynski, S. Czerniak Z.
Quantitative determination of amino acids using photometry of negative printed chromatograms
Ann Univ MC Sklodowska 1966;21:125-134
Ann Univ Mariae Curie Sklodowska Med. 1966;21:125-34. Article in Polish

1966

Krzeczkowska. 1., Czerniak. Z., Burzynski, S.
The application ofthe negative printed chromatograms for quantitative determination of free amino acids in the blood of healthy people
Ann Univ MC Sklodowska 1966; 2 1: 313-322

1965

Krzeczkowska, 1., Burzynski, S., Czerniak. Z.
Investigations on the possibility ofthe determination of mushroom species on the basis ofthe composition of their amino acids
Ann Univ MC Sklodowska 1965;20:221-229

1965

Krzeczkowska, L, Czerniak, Z., Burzynski, S.
Free and bound amino acids of some edible mushrooms
Ann Univ MC Sklodowska 1965;20:303-312

1964
http://www.ncbi.nlm.nih.gov/m/pubmed/5893108
Krzeczkowska, L, Czerniak, Z., Burzynski, S.
Bound amino acids of some edible mushrooms
Ann Univ MC Sklodowska 1964;19:329-336
Ann Univ Mariae Curie Sklodowska Med. 1964;19:329-36. Article in Polish

1964
http://www.ncbi.nlm.nih.gov/m/pubmed/5893107
Krzeczkowska, L, Burzynski, S., Czerniak, Z.
Free amino acids of some edible mushrooms
Ann Univ MC Sklodowska 1964;19:321-328
Ann Univ Mariae Curie Sklodowska Med. 1964;19:321-8. Article in Polish

SELECTED ABSTRACTS OF PRESENTATIONS BY S.R. BURZYNSKI AND ASSOCIATES

11/16 – 22/2010
Burzynski, S.R, Weaver, RA, Janicki, T.J., Burzynski, G.S., Szymkowski, B., Acelar, S.S.
OT-15
Preliminary results of a phase II study of antineoplastons A 10 and AS2-1 (ANP) in adult patients with recurrent mixed gliomas
Presented at the 15th Annual Scientific Meeting ofthe Society for Neuro-Oncology; November 16-22, 2010; Montreal, Quebec, Canada

11/16 – 22/2010
Patil, S., Burzynski, S.R, Mrowczynski, E., Grela, K.
CB-15
Targeting microRNAs in glioma cells with antineoplastons
Presented at the 15th Annual Scientific Meeting ofthe Society for Neuro-Oncology; November 16-22, 2010; Montreal, Quebec, Canada

6/20- 23/2010
Burzynski, S.R, Weaver, RA. Janicki, T.. E. Szymkowski, B.•Acelar. S.S., Burzynski, G.S.
A phase II study of antineoplaston A 10 and AS2-1 injections in children with low-9rade astrocytomas
Presented at the 14th International Symposium on Pediatric Neuro-Oncology (ISPNO); June 20-23, 2010; Vienna. Austria

6/20 – 23/2010
Patil, S., Burzynski, S.R. Mrowczynski, E.• Grela, K.
Antineoplastons initiate caspase induced apoptosis by suppressing survivin expression in U87 glioblastoma cells
Presented at the 14th International Symposium on Pediatric Neuro-Oncology (ISPNO); June 20-23, 2010; Vienna. Austria

5/11 – 14/2009
Burzynski, S.R.•Janicki, T.J.•Weaver. RA. Szymkowski, B.• Burzynski, G.S.
Phase II study of antineoplastons A 10 and AS2-1 in patients with brainstem glioma
Protocol BC-BT-11
Presented at the 3rd Quadrennial Meeting oftheWorld Federation ofNeuro-Oncology jointly with the 6th Meeting ofthe Asian Society for Neuro-Oncology; May 11-14. 2009; Yokohama. Japan

5/11 – 14/2009
Weaver. RA. Szymkowski, B.• Burzynski, S.R.
Over a 10-year survival andcomplete response ofa patientwith diffuse intrinsic brainstem glioma (DBSG) treated with antineoplastons (ANP)
Presented at the 3rd Quadrennial Meeting ofthe World Federation ofNeuro-Oncology jointly with the 6th Meeting ofthe Asian Society for Neuro- Oncology; May 11-14. 2009; Yokohama. Japan

5/11 – 14/2009
Patil, S., Burzynski, S.R., Chittur, S., Mrowczynski, E., Grela, K.
Antineoplastons inhibit MCM complex in glioblastoma cells
Presented at the 3rd Quadrennial Meeting ofthe World Federation ofNeuro-Oncology jointly with the 6th Meeting ofthe Asian Society for Neuro-Oncology; May 11-14. 2009; Yokohama. Japan

4/21 – 25/2009
Burzynski, S.R.
New research on molecular mechanisms and prevention of Alzheimer's disease
Presented at the 17th Annual world Congress on Anti-Aging Medicine and Regenerative Biomedical Technologies, Spring 2009 Session; Aprii 21-April 25, 2009; Orlando, Florida

3/19 – 21/2009
Burzynski, S.
Life extension through application ofchromatin remodeling agents
Presented at the 7th Anti- Aging Medicine World Congress & Medispa; March 19-March 21, 2009; Monte-Carlo, Monaco

Marquis, A , Kubove, E., W alczak, M., Burzynski, S.
Hepatocellular carcinoma, recurrent after standard therapy, ~llrrP~~flllht trP::~fPrt with :~ rnmhin::~tinn nft::~rnPIPrt thPr::~niP~ PrP~PntPrt ::~t thP ?nth lntPrn::~tinn::~l r.nnnrP~~ nn

SELECTED ABSTRACTS OF PRESENTATIONS BY S.R. BURZYNSKI AND ASSOCIATES

Burzynski, S.R, Weaver, RA, Janicki, T.J., Burzynski, G.S., Szymkowski, B., Acelar, S.S.
OT-15
Preliminary results of a phase II study of antineoplastons A 10 and AS2-1 (ANP) in adult patients with recurrent mixed gliomas
Presented at the 15th Annual Scientific Meeting ofthe Society for Neuro-Oncology; November 16-22, 2010; Montreal, Quebec, Canada

Patil, S., Burzynski, S.R, Mrowczynski, E., Grela, K.
CB-15
Targeting microRNAs in glioma cells with antineoplastons
Presented at the 15th Annual Scientific Meeting ofthe Society for Neuro-Oncology; November 16-22, 2010; Montreal, Quebec, Canada

Burzynski, S.R, Weaver, RA. Janicki, T.. E. Szymkowski, B.•Acelar. S.S., Burzynski, G.S.
A phase II study of antineoplaston A 10 and AS2-1 injections in children with low-9rade astrocytomas
Presented at the 14th International Symposium on Pediatric Neuro-Oncology (ISPNO); June 20-23, 2010; Vienna. Austria

Patil, S., Burzynski, S.R. Mrowczynski, E.• Grela, K.
Antineoplastons initiate caspase induced apoptosis by suppressing survivin expression in U87 glioblastoma cells
Presented at the 14th International Symposium on Pediatric Neuro-Oncology (ISPNO); June 20-23, 2010; Vienna. Austria

Burzynski, S.R.•Janicki, T.J.•Weaver. RA. Szymkowski, B.• Burzynski, G.S.
Phase II study of antineoplastons A 10 and AS2-1 in patients with brainstem glioma
Protocol BC-BT-11
Presented at the 3rd Quadrennial Meeting oftheWorld Federation ofNeuro-Oncology jointly with the 6th Meeting ofthe Asian Society for Neuro-Oncology; May 11-14. 2009; Yokohama. Japan

Weaver. RA. Szymkowski, B.• Burzynski, S.R.
Over a 10-year survival andcomplete response ofa patientwith diffuse intrinsic brainstem glioma (DBSG) treated with antineoplastons (ANP)
Presented at the 3rd Quadrennial Meeting ofthe World Federation ofNeuro-Oncology jointly with the 6th Meeting ofthe Asian Society for Neuro- Oncology; May 11-14. 2009; Yokohama. Japan

Patil, S., Burzynski, S.R., Chittur, S., Mrowczynski, E., Grela, K.
Antineoplastons inhibit MCM complex in glioblastoma cells
Presented at the 3rd Quadrennial Meeting ofthe World Federation ofNeuro-Oncology jointly with the 6th Meeting ofthe Asian Society for Neuro-Oncology; May 11-14. 2009; Yokohama. Japan

Burzynski, S.R.
New research on molecular mechanisms and prevention of Alzheimer's disease
Presented at the 17th Annual world Congress on Anti-Aging Medicine and Regenerative Biomedical Technologies, Spring 2009 Session; Aprii 2 1-April 25, 2009; Orlando, Florida

Burzynski, S.
Life extension through application ofchromatin remodeling agents
Presented at the 7th Anti- Aging Medicine World Congress & Medispa; March 19-March 21, 2009; Monte-Carlo, Monaco

Marquis, A , Kubove, E., W alczak, M., Burzynski, S.
Hepatocellular carcinoma, recurrent after standard therapy, ~llrrP~~flllht trP::~fPrt with :~ rnmhin::~tinn nft::~rnPIPrt thPr::~niP~ PrP~PntPrt ::~t thP ?nth lntPrn::~tinn::~l r.nnnrP~~ nn

Anti-Cancer Treatment; February 3-February 6, 2009; Paris, France

W eaver, R, De Leon, L, Burzynski, S_
A complete response in a patient with inoperable adenocarcinoma ofthe head of the pancreas treated with a combination of gene-targeted therapies
Presented at the 20th International Congress on Anti-Cancer Treatment; February 3-February 6, 2009; Paris, France

Burzynski, S.R.
The Coming Pandemic of Liver Cancer
In Search of Genomic Solutions. Presented at the 16th Annual World Congress of A 4 M, Winter 2008 Session; December 12 – December 15, 2008; Las Vegas, Nevada

Burzynski, S.R., Weaver, R., Janicki, T., Szymkowski, B., Samuel, S., Burzynski, G.
Phase II study of antineoplastons A 10 and AS2-1 (ANP) in patients with newly diagnosed anaplastic astrocytoma:
A preliminary report
Presented at the 13th Annual Scientific Meeting ofthe Society for Neuro-Oncology; November 20- November 23, 2008; Las Vegas, Nevada

Burzynski, S.R., Patil, S., Chittur, S., Mrowczynski, E., Grela, K.
Antineoplaston AS2-1 affects cell cycle checkpoints leading to apoptosis in human glioblastoma cells
Presented at the 13th Annual Scientific Meeting of the Society for Neuro-Oncology; November 20-November 23, 2008; Las Vegas, Nevada

Burzynski, S.R., Patil, S., llkowska-Musial, E., Chittur, S., Gupta, V., Sarangi, R.
Pathway analysis ofthe effect of chromatin remodeling agent phenylbutyrate on the brains of honeybees
Presented at Neuroscience 2008; November 15-November 19, 2008; Washington D.C.

Burzynski, S.R.
Practical Application of Gene Silencing Theory ofAging
Life Extension in Animals and Human Clinical Trials
Presented at the Dubai Congress on Anti-Aging and Aesthetic Medicine (DCAAAM); November 7- November 9, 2008; Dubai

Burzynski, S.R.
Antineoplastons and Targeted Gene Therapy
Presented at ACAM Scientific Conference; October 15-0ctober 19, 2008; Las Vegas, Nevada

Burzynski, S.R., Weaver, R., Janicki, T., Szymkowski, B., Walczak, M., Burzynski, G.
Phase II study of antineoplastons A 10 and AS2-1 infusions (ANP) in patients with recurrent anaplastic astrocytoma
Presented at the European Association for NeuroOncology (EANO); September 12-September 14, 2008; Barcelona, Spain

Patil, S., Burzynski, S.R., Chittur, E., Mrowczynski, K.G.
The ingredients of antineoplaston AS2-1 down- regulate glycolysis pathways in glioblastoma cells
Presented at the European Association for NeuroOncology (EANO); September 12-September 14, 2008; Barcelona, Spain

Burzynski, S.R.
Practical application ofgene silencing theory of aging
Life extension in animal testing and human clinical trials
Presented at the European Congress on Anti-Aging & Aesthetic Medicine (ECAAAM); September 11-September 14, 2008; Dusseldorf, Germany

Burzynski, S.R., Weaver, R., Janicki, T., Walczak, M., Szymkowski, B., Samuel, S.
Phase II study of antineoplastons A 10 and AS2-1 (ANP) in children with optic pathway glioma:
A preliminary report
Presented at the 13th International Symposium on Pediatric Neuro-Oncology; June 29.July 2, 2008; Chicago, Illinois

Burzynski, S.R.
Genome, Epigenome and Aging
Presented at the First Annual Iberian Congress on Anti-Aging Medicine and Biomedical Technologies; May 29-31, 2008; Estoril, Portugal

Burzynski, S.R_
Personalized Cancer Treatment in Genomics Era_
Presented at the First Annual Iberian Congress on Anti-Aging Medicine and Biomedical Technologies; May 29-31, 2008; Estoril, Portugal

Burzynski, S.R.
Practical application of gene silencing theory of aging
Life extension in animals and human clinical trials
Presented at the 16th Annual W orld Congress on Anti-Aging Medicine and Regenerative Biomedical Technologies; April 25-27, 2008; Orlando, Florida

Burzynski, S.R.
Antineoplaston peptides in treating cancer
Presented at the 2008 Orthomolecular Health- Medicine conference; February 29-March 2, 2008; San Francisco, California

Burzynski, S.R.
Anti-Aging peptides- a new frontier in healing
Presented at the 2008 Orthomolecular Health- Medicine conference; February 29-March 2, 2008; San Francisco, California

Burzynski, S.R.
Genomic approach to cancer treatment
Presented at the 15th Annual World Congress on Anti-Aging Medicine and Regenerative Biomedical Technologies; December 12-15, 2007; Las Vegas, Nevada

Burzynski,S.R.
GenomicsinCancerTreatment
Presentedatthe1stAnnualIndiaConferenceonAnti-Aging and Regenerative Medicine; November 16-18, 2007; Mumbai, India

Burzynski, S.R.
Epigenomic Approach to Anti-Aging
Presented at the 1st Annual India Conference on Anti- Aging and Regenerative Medicine; November 16-18, 2007; Mumbai, India

Burzynski, S.R., Weaver, RA , Szymkowski, B.
A case report ofa complete response and20-year suO/ivai of a patient with a recurrent, diffuse. intrinsic brainstem anaplastic astrocytoma_
Presented at the Society for Neuro- Oncology 12th Annual Scientific Meeting; November 15-18, 2007; Dallas, Texas

Patil, S., Burzynski, S.R., Mrowczynski, E., Grela, K.
Phenylacetylglutamine (PG) and phenylacetate (PN) interact additively to produce detachment-induced apoptosis/anoikis in glioblastoma cells
Presented at the Society for Neuro-Oncology 12th Annual Scientific Meeting; November 15-18, 2007; Dallas, Texas

Burzynski, S.R., Tempczyk-Russell, A., llkowska-Musial, E.
Amyloid precursor protein (APP) and related protein fragmentation in consolidation of memory
Presented at Neuroscience 2007, the Society's Annual Meeting; November 3-7, 2007; Sand Diego, California

Burzynski, S.R.
Epigenomic approach to anti-aging
Presented at:
4th Congresso lnternacional de Antienvelhecimento; October 26-27, 2007; Sao Paulo, Brazil

Burzynski, S.R.
Nutrition and ageing :
Gene silencing or gene activation
Presented at: 10th European Nutrition Conference; July 10-13, 2007; Paris, France

Burzynski, S.R.
La solution genetique contre le vieillissement Presented at:
Anti-Aging Medicine World Congress; March 22-24, 2007; Monte Carlo

Burzynski, S.R.
Genetics of Brain Aging (II)
Genetic Mechanisms in Encoding and Consolidation of Memory
Presented at:
14th Annual International Congress on Anti-Aging Medicine; December 7-10, 2006; Las Vegas, Nevada

Burzynski, S.R., Janicki, T.J., Weaver, RA , Szymkowski, B.J., Khan, M.l., Dolgopolov, V.
Treatment of multicentric brainstem ~liomas with Antineoplastons (ANP) A 10 and AS2-1
Presented at the Society for Neuro-

Respectful Insolence or Hipocritical Oath

The purpose of this blog is to combat the “misdirection,” “misinformation,” “disinformation,” and lies posted by entities like Orac (HerOrac {“Hero” “Orac”}, OracQuack) and his “Oracolytes” on the “Respectful Insolence” blog on:
http://www.scienceblogs.com/Insolence

Orac and friends ignore “facts,” “fact-checking,” “research,” citations and references like the plague, and instead engage in hyperbole

They refer to those who don’t agree with them as “trolls,” “insane,” and use other inane adolescent terms in their attempts at misdirection away from dealing with what they do not want to recognize

Like:
http://fight4yourhealth.com/answers/taiwan-cancer-therapy
and information about research done in Taiwan, ROC and China re CDA-II (CDA-H / CDA-2):
6/8/2012 (5/22/2012)
http://www.ncbi.nlm.nih.gov/m/pubmed/22627135
( http://www.sciencedirect.com/science/article/pii/S0006291X1200945X )
1/2009 (8/9/2008)
http://www.ncbi.nlm.nih.gov/m/pubmed/18761050
( http://www.sciencedirect.com/science/article/pii/S0278691508004249 )
9/2008
http://www.ncbi.nlm.nih.gov/m/pubmed/19175987
4/2006 (10/17/2005)
http://www.ncbi.nlm.nih.gov/m/pubmed/16229933
( http://www.sciencedirect.com/science/article/pii/S0278691505002875 )
2003
http://www.ncbi.nlm.nih.gov/m/pubmed/12943172
( http://www.worldscientific.com/doi/abs/10.1142/S0192415X0300103X )
PDF
[ http://www.worldscientific.com/doi/pdf/10.1142/S0192415X0300103X ]
PDF+
{ http://www.worldscientific.com/doi/pdfplus/10.1142/S0192415X0300103X }
References

1/2003
http://www.ncbi.nlm.nih.gov/m/pubmed/12508353
( http://www.wjgnet.com/1007-9327/full/v9/i1/65.htm )
PDF
[ http://www.wjgnet.com/1007-9327/9/65.pdf ]
2001
http://www.ncbi.nlm.nih.gov/m/pubmed/11321484
( http://www.worldscientific.com/doi/abs/10.1142/S0192415X01000101 )
PDF
[ http://www.worldscientific.com/doi/pdf/10.1142/S0192415X01000101 ]
PDF+
{ http://www.worldscientific.com/doi/pdfplus/10.1142/S0192415X01000101 }